Business Context and Reporting Period
This Form 8-K reports on the 2022 Annual Meeting of Stockholders held by Silverback Therapeutics, Inc. on June 10, 2022. The filing details the voting results for the election of directors and the ratification of the independent registered public accounting firm. As of the record date (April 11, 2022), 35,145,281 shares of common stock were outstanding and entitled to vote.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting outcomes.
Material Changes
No material financial changes are reported in this filing. The document serves to disclose the outcome of shareholder votes rather than financial performance updates.
Guidance, Outlook, and Management Commentary
There is no guidance, outlook, or management commentary regarding future financial performance or operational risks in this filing. The document confirms the ratification of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2022.
Important Facts for Investors
- Director Election Results: Andrew Powell, J.D., and Peter Thompson, M.D., were elected as Class II directors to serve until the 2025 Annual Meeting.
- Voting Support for Directors: Andrew Powell received 19,679,263 votes for (with 1,860,328 withheld), while Peter Thompson received 16,559,581 votes for (with 4,980,010 withheld).
- Broker Non-Votes: There were 6,690,733 broker non-votes for both director proposals.
- Accounting Firm Ratification: Stockholders overwhelmingly ratified the selection of Ernst & Young LLP, with 28,164,863 votes for, 44,709 against, and 20,752 abstentions.
- Company Name Discrepancy: The request metadata lists "ARS Pharmaceuticals, Inc.," but the filing text explicitly identifies the registrant as "Silverback Therapeutics, Inc." (SBTX).